Dexlansoprazole
- Generic Name
- Dexlansoprazole
- Brand Names
- Dexilant
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 138530-94-6
- Unique Ingredient Identifier
- UYE4T5I70X
- Background
Dexlansoprazole is a new generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of Lansoprazole, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes Pa...
- Indication
Dexlansoprazole is a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for:
- Associated Conditions
- Erosive Esophagitis, Heartburn, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Healed erosive esophagitis
- Associated Therapies
- -
Effect of Dexlansoprazole on Bone Homeostasis
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 115
- Registration Number
- NCT01216293
Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2016-12-19
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 40
- Registration Number
- NCT01149395
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT01093755
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole in Pediatric Subjects With Symptomatic Gastroesophageal Reflux Disease
- First Posted Date
- 2010-01-08
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 36
- Registration Number
- NCT01045096
Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy
Not Applicable
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00928161
A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2011-04-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 305
- Registration Number
- NCT00627016
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath